Psychiatry AtlasMedication guide · United States

Antidepressant called a monoamine oxidase inhibitor (MAOI)

Tranylcypromine (Parnate)

Generic name
tranylcypromine sulfate
Brand names
Parnate
Medication class
MAOI antidepressant
Forms covered
Parnate oral tablets

Article updated: 2026-10-24 · Sources last checked: 2026-11-05

Medication Safety Alerts

FDA Boxed Warning

Parnate oral tablets.

Antidepressants can increase suicidal thoughts and behaviors in children, adolescents and young adults; monitor all patients. Tyramine-rich foods or drinks and certain interacting medicines can trigger a dangerous hypertensive crisis during treatment or after stopping. Follow the prescribed food restrictions, interaction precautions and medication-free intervals. Parnate is not approved for children.

Tranylcypromine, known as Parnate, is an MAO inhibitor for depression that has not responded adequately to other antidepressants. It requires careful dietary and medication restrictions.

What to expect: Full benefit may take three weeks or longer.

Warning signs
Sources last checked:
2026-11-05

What is this medicine used for?

FDA-approved uses

  • Major depressive disorder after inadequate response to other antidepressants — Adults. Not indicated for initial MDD treatment.Parnate oral tablets.

What should I expect?

Full benefit may take three weeks or longer. Blood-pressure changes or difficulty sleeping can occur earlier.

Review mood, sleep and functioning with the prescriber, alongside blood-pressure symptoms and whether the diet and interaction plan is workable.

How do I take it safely?

Take the divided doses exactly as prescribed. Follow the product’s written low-tyramine food plan during treatment and for two weeks afterward. Avoid aged or fermented foods and drinks identified in that plan, alcohol and unreviewed cold, allergy, stimulant or weight-loss products.

Many antidepressants, stimulants, decongestants, dextromethorphan, triptans, buspirone and certain pain medicines are contraindicated. Have both products’ labels checked before switching. A one-week interval is not a universal safe rule; many combinations require longer, including at least five weeks after fluoxetine before an MAOI.

Check blood pressure and symptoms of faintness, and monitor mood, mania, liver symptoms and blood sugar when relevant. Discuss pregnancy. The label advises against breastfeeding during treatment. Pediatric safety is not established; older adults have greater fainting risk.

Use a clinician-led stopping plan because withdrawal can be severe. A missed dose should be skipped if the next is near; never double. Maintain the food restrictions and checked interaction waiting periods after stopping.

Do not use with pheochromocytoma or a paraganglioma that releases catecholamines, hormones that can raise blood pressure. Seizure history and low-blood-sugar risk need review.

Do not use this product after a known allergy to its active medicine or ingredients; tell the pharmacist about previous medication reactions.

What side effects should I know about?

  • Dry mouth, dizziness, insomnia or sedation, headache, constipation and tremor.

Tell your prescriber about effects that are persistent, troublesome, or interfere with daily life.

Which warning signs need help?

  • Contact the prescriber promptly for new suicidal thoughts, worsening depression or unusual behavior. Use emergency care if there is immediate danger or the person cannot stay safe.
  • A sudden severe headache, stiff neck, pounding heartbeat, chest pain or confusion can signal a hypertensive crisis. Stop the medicine and obtain emergency assessment. Tyramine foods and interacting drugs can trigger this during treatment or after stopping.
  • Fever with agitation, diarrhea, tremor or rigid muscles can signal serotonin syndrome. Severe symptoms, seizures, collapse or suspected overdose require emergency care. Report jaundice, faintness, low-blood-sugar symptoms or severe withdrawal promptly.

What else should I know to stay safe?

  • Follow the product-specific low-tyramine restrictions during treatment and for two weeks afterward. Avoid alcohol and unreviewed cold, allergy, stimulant or weight-loss products.
  • Many antidepressants, stimulants, decongestants, triptans, buspirone and certain pain medicines are contraindicated. Check both medicines before switching: one week is not a universal safe interval, and fluoxetine requires at least five weeks before an MAOI. Do not stop abruptly.
  • Do not use with pheochromocytoma, a catecholamine-releasing paraganglioma or product allergy. Monitor blood pressure, falls, liver health, mood, seizures and blood sugar when relevant. Discuss pregnancy; the label advises against breastfeeding, and pediatric safety is not established.

Urgent help and crisis support · Emergency & Crisis Resources (US)

What can help day to day?

  • Feeling well after the last tablet does not mean another antidepressant is safe to start. The effect on the enzyme that breaks down chemical messengers lasts longer than the drug itself.
  • A home blood-pressure number is not needed before seeking help for a sudden severe headache, chest pain or confusion. These symptoms can signal a dangerous reaction.

How does it work?

Tranylcypromine changes nerve-cell communication by reducing the breakdown of a group of chemical messengers called monoamines. It does this by inhibiting monoamine oxidase, an enzyme that helps process these chemicals. This is the proposed basis of its antidepressant action, although the full sequence leading to symptom improvement is not completely understood.

Explore medication science

How was this medicine developed?

Parnate received FDA approval in 1961. Its current US role is major depression in adults who have not responded adequately to other antidepressants; serious interactions shape how it is used.

How do I say the name?

Tranylcypromine: tran-il-SIP-roe-meen. Capital letters show the stressed syllable.

Sources and References

Sources support the U.S. products described here. Product instructions can differ; use the information supplied with your own medicine.

  1. Parnate prescribing information — mechanism explanation

    Scope: Mechanism explanation only. Source sections checked: 5.9 Persistence of MAO Inhibition after Discontinuation; 7.2 Tyramine-Containing Foods and Beverages; 12.1 Mechanism of Action; 12.2 Pharmacodynamics..

  2. Tranylcypromine: FDA approval history
  3. Tranylcypromine: patient medicine information
  4. Parnate: Package Insert / Prescribing Information / MOA
  5. Tranylcypromine: FDA prescribing information
  6. Nardil: prescribing information
  7. Tranylcypromine: verified neutral parent, PubChem CID 5530
  8. What Is a Neurotransmitter? — mechanism explanation

    Scope: Mechanism explanation only. Source sections checked: How Neurotransmitters Work; Types of Neurotransmitters..

  9. Serotonin syndrome: MedlinePlus Medical Encyclopedia
  10. Monitoring a person during and after antidepressant switching – NHS SPS - Specialist Pharmacy Service – The first stop for professional medicines advice

Giving medicine safely to children: family guide (PDF, 3 pages)

How information is checked

Was this article helpful?

Was this article helpful?

Sends your choice, article identifier, edition and optional issue to Psychiatry Atlas. No name, email or medical details are requested. Daily network codes help prevent spam; hosting may process technical information. This is not a promise of anonymity. Privacy details.

Enable JavaScript to send feedback.

Suggest a missing topic or describe a correction. Please keep personal medical information out of website feedback.

Back to top